Scientific Publications

HIV/AIDS and AntiViral-HyperActivation Limiting Therapeutics (AV-HALT)

Baev, D., Calarota, S.A., Testori M., and Lori, F. Pre-treatment expression of Ki-67 proliferation marker predicts HIV-1 suppression after antiretroviral therapy. Poster abstract 5009 XVIII International AIDS Conference, 18-23 July 2010, Vienna, Austria.
- Poster  abstract 5009

Katabira, E. 1, Cahn, P. 2, Lange, J. 3, Macerati, R. 4, Baev, D. 4, Calarota, S.A. 4, De Forni, D. 4, Stevens, M.R. 5, Lisziewicz, J. 6, Lori, F. 4, for the VS411 Study Group 1 Uganda, 2 Argentina, 3 Netherlands, 4 Italy, 5 United States, 6 Hungary. Both immune activation and viral load are reduced within 28 days by VS411, the first antiviral-hyperactivation limiting therapeutic (AV-HALT). A phase II study. Poster abstract 4916 XVIII International AIDS Conference, 18-23 July 2010, Vienna, Austria.
- Poster  abstract 4916

De Forni, D., Stevens, MR., and Lori, F. Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in human immunodeficiency virus/acquired immunodeficiency syndrome. British Journal of Pharmacology 2010.

Lori F., De Forni D., Stevens M. Development of VS411, a Virostatic fixed-dose combination (FDC) designed to inhibit both HIV and immune hyperactivation. Poster abstract 11. HIV DART 2008: frontiers in drug development for antiretroviral therapies, 9-12 December 2008, Rio Grande, Puerto Rico.

Lori, F. Treating HIV/AIDS by reducing immune system activation: the paradox of immune deficiency and immune hyperactivation. Current Opinion in HIV and AIDS 3:99-103, 2008.

Foli, A., Maiocchi, M.A., Lisziewicz, J., and Lori, F. A Checkpoint in the Cell Cycle Progression as a Therapeutic Target to Inhibit HIV Replication. J Infect Dis. 196(9):1409-15, 2007.

Maserati, R., Foli, A., Tomasoni, L., Sighinolfi, L., Maggiolo, F., Sacchini, D., Di Pietro, M., Bertelli, D., Tinelli, C., and Lori, F.: Effects of Structured Treatment Interruptions on Metabolilc, Anthrompometric, Immunologic, and Quality of Life Outcomes in HIV-Positive Adults on HAART. Current HIV Research 5:337-43, 2007.

Lori, F., Foli, A., Kelly, L.M., Lisziewicz, J.: ViroStatics: A New Class of Anti-HIV Drugs. Curr Med Chem. 14: 233-41, 2007.

Lori, F., Foli, A., Lisziewicz, J.: Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options. Current Opinion in HIV and AIDS 2:14-20, 2007.

Lori, F., Foli, A., Groff, A., Lova, L. MS, Whitman, L., Bakare, N., Pollard, R.B., Lisziewicz, J.: Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms AIDS. Jul 22;19(11): 1173-8, 2005.

Lori, F., Pollard, R.B., Whitman, L., Bakare, N., Blick, G., Shalit, P., Foli, A., Peterson, D., Tennenberg, A., Schrader, S., Rashbaum, B., Farthing, C., Herman, D., Norris, D., Greiger, P., Frank, I., Groff, A., Lova, L., Asmuth, D., Lisziewicz, J.: Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. AIDS Res Hum Retroviruses. 21(4): 263-272, 2005.

Lova, L., Groff, A., Ravot, E., Comolli, G., Xu, J., Whitman, L., Lewis, M., Foli, A., Lisziewicz, J., Lori, F.: Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes. AIDS, Jan 28;19(2): 137-144, 2005.


PHPC Assay

Calarota, S.A., Foli, A., Maserati, R., Baldanti, F., Paolucci, S., Young, M.A., Tsoukas, C.M., Lisziewicz, J., and Lori, F. HIV-1-specific T-cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol 180:5907-5915, 2008.

S. A. Calarota, A. Foli, R. Maserati, V. La Rosa , F. Baldanti, S. Paolucci, C. M. Tsoukas, J. Lisziewicz, F. Lori "Antigen-specific T Lymphocytes with High Proliferative Capacity Inversely Correlate with Viral Replication in Chronically Untreated HIV-1-infected Individuals" Poster # P2.4/02/BPD, 11th European AIDS Conference / EACS, Madrid, Spain, Oct 24-27, 2007.